INTRODUCTION
Head and neck cancers include cancers of the oral cavity, oropharynx, hypopharynx and larynx. Among the annual deaths in Taiwan in 2019, 50,232 deaths were due to cancers, of which 3425 deaths (14.5%) occurred due to oral cancer (from the Ministry of Health and Welfare of Taiwan). Oral cancer refers to malignancies arising in the intra-oral sites including the lips, tongue, salivary gland, gingiva, the floor of the mouth, the buccal mucosal surface and others. Oral squamous cell carcinoma (OSCC) is the most prevalent malignant neoplasm in oral cancer, and its mortality has increased over the past decade. Approximately 50% of patients with oral cancer have cervical lymph node metastasis at the time of diagnosis and experience poor outcomes. Unfortunately, the 5-year survival rate
of patients with oral cancer has not significantly improved despite the availability of multiple treatment modalities, including surgery, radiotherapy, chemotherapy and target therapy.\textsuperscript{2,6,7} Metastasis development in cancer involves multiple steps, in which malignant cells spread from the origin tumour to colonize distant organs.\textsuperscript{8} These basic steps are dependent on the type of cancer. Different cancers have different process steps, signalling pathways and development rates as they colonize distant organs.

Metabolic reprogramming is a major hallmark of cancer and plays an important role in the malignant properties of cancer cells.\textsuperscript{9,10} Moreover, metabolism contributes to the malignant phenotype, signal transduction, tumorigenesis and metastasis of cancer cells.\textsuperscript{11-14} However, the mechanism by which cancer cells take advantage of bioenergetics to modulate the malignant phenotype has not yet been elucidated.

Ubiquitination is an important cellular mechanism for the degradation of abnormal or short-lived proteins. The ubiquitin-conjugating enzyme E2 (UBE2) family is involved in ubiquitination.\textsuperscript{15} In our study, we analysed the members of the UBE2 family that were differentially expressed in patients with head and neck squamous cell carcinoma (HNSCC). We found that UBE2C was upregulated in tumour tissues and was associated with poor overall survival in HNSCC. Meanwhile, knockdown of UBE2C inhibited the glycolysis pathway in HNSCC cells, illustrating that UBE2C levels are correlated with the expression of glycolysis enzymes in patients with HNSCC. However, the interplay between UBE2C and the glycolysis pathway in HNSCC development and progression remains elusive.

\section{MATERIALS AND METHODS}

\subsection{In silico mRNA profiles and Kaplan–Meier analysis of the UBE2 family}

The mRNA expression of the UBE2 family was determined using TCGA dataset. Kaplan–Meier analysis (overall survival) was performed using the TCGA dataset (ENCORI, https://starbase.sysu.edu.cn/index.php).

\subsection{Cell lines and culture conditions}

SAS and CAL27 cell lines from human tongue squamous cell carcinoma. CAL27 was purchased from ATCC (#CRL-2095). SAS was provided from Dr. Michael Hsiao at Academia Sinica in Taiwan. HNSCC cell lines CAL27 and SAS were cultured in DMEM with 10% FBS and 1% PSG.

\subsection{Lentivirus infection}

Lentivirus vector control (pLKO-1-shLuc967) and shUBE2C shRNA viral supernatant (TRCN0000004241, TRCN0000368994) were purchased from the National RNAi Core Facility (Taipei, Taiwan; target sequences are provided in Table S3). Viral supernatants used to infect SAS or CAL27 with 8 \(\mu\)g/ml polybrene. After 72h, cells were selected using 2 \(\mu\)g/ml puromycin.

\subsection{Growth curve assay}

Cells (2000 cells/well for SAS/shluc, SAS/shUBE2C-1, SAS/shUBE2C-2, CAL27/shluc, CAL27/shUBE2C-1 and CAL27/shUBE2C-1) were seeded in a 96-well plate for 24–72h (incubated at 37°C with 5% CO\(_2\)). The cell growth curve was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

\subsection{Pathway and upstream regulator analysis}

We downloaded GSE32873 (as an mRNA microarray of PC3/knockdown UBE2C compared with PC3/knockdown control) \cite{18} and fold change analysis was performed using GEO2R from Gene Expression Omnibus (GEO) website. The UBE2C interaction network pathway and upstream regulator were generated using Ingenuity Pathway Analysis (IPA). To identify upstream regulators related with UBE2C regulation, we analysed differentially expression gene (793 genes from GEO2R) in PC3/knockdown UBE2C compared with PC3/knockdown control and filtered upstream regulator according to z-score (inhibition, < -2.0). Based on IPA, we identified HIF1A that putatively associated with UBE2C-knockdown (Table S2).

\subsection{Cell invasion and migration assay}

HNSCC cell migration and invasion capabilities were determined using transwell chambers, as previously described \cite{29}. First, the cells were resuspended in serum-free medium (2 \(\times\) 10\(^5\) cells/ml) and loaded into transwell chambers (upper chamber) in 100 \(\mu\)l. After 48h, the cells were stained with crystal violet and measured (bottom chamber) under a light microscope.

\subsection{Colony formation assay}

The stable lines were plated in a six-well plate at a density of 4000 cells/well. After 7 days, the cells were fixed and stained using crystal violet. The number of colonies was counted using the NIH Image J software.

\subsection{Western blot analyses}

A total of 20 \(\mu\)g protein was extracted from SAS (SAS/shLUC, SAS/shUBE2C-1 and SAS/shUBE2C-2) and CAL27 (CAL27/shLUC and CAL27/shUBE2C-1 and CAL27/shUBE2C-2) cells and loaded onto 15% SDS-PAGE gel for electrophoresis, and then transferred to PVDF. The antibodies were listed in Table S3.
2.9 | Quantitative reverse transcription PCR

The stable cell lines SAS/shLUC, SAS/shUBE2C-1, CAL27/shLUC and CAL27/shUBE2C-1 (3 × 10^5 cells/dish) were separately plated in 6-cm culture plates and incubated overnight at 37°C with 5% CO₂. The SAS/shUBE2C-1 and CAL27/shUBE2C-1 cells were then treated with a CoCl₂ (HIF-α inducer) for 48 h, followed by total RNA extraction for quantitative reverse transcription PCR (RT-qPCR analysis (SYBR system). RT-qPCR was performed using the appropriate primers (Table S4).

2.10 | Statistical analysis

A chi-square test was performed in order to identify the association of UBE2C with sex, tumour stage, tumour size and lymph node status. To identify significant differences between the treatment groups, a two-tailed Student’s t-test was performed. Spearman’s correlation was used to determine the correlations between parameters. Statistical significance was set at p < 0.05.

3 | RESULTS

3.1 | In silico profiles of the UBE2 family members in HNSCC

We evaluated the expression of the UBE2 family in HNSCC, we used The Cancer Genome Atlas (TCGA) database, including 43 pair and total HNSCC specimens (normal = 44 and tumour = 522). UBE2A, UBE2C, UBE2I, UBE2L3, UBE2O, UBE2Q1, UBE2S, UBE2V2, UBE2W and UBE2Z levels were significantly upregulated in patients with HNSCC (Figure 1 and Figure S1). We then examined the overall survival rates of UBE2A, UBE2C, UBE2I, UBE2L3, UBE2O, UBE2Q1, UBE2S, UBE2V2, UBE2W and UBE2Z in an online survival analysis. High UBE2L3 and UBE2Q1 expression were significantly associated
with poor overall survival (Figure 2). Later, we compared UBE2C, UBE2L3 and UBE2Q1 in transmission organization. UBE2C and UBE2L3 were upregulated in metastatic tissues (Figure S2). In overall survival analysis, UBE2C expression was not significantly associated with overall survival in HNSCC patients. However, previous studies showed that UBE2C was upregulated in HNSCC patients and its expression was associated with lymph node metastasis in tongue squamous cell carcinoma patients.\textsuperscript{16,17} Therefore, we focus on UBE2C for further investigation of its molecular mechanism in HNSCC, we used TCGA database. We found that high UBE2C levels in patients

**TABLE 1** Association of UBE2C expression with clinicopathological characteristics in 444 patients with HNSCC

| Variables          | Item     | Patient No. | Low (No. %) | High (No. %) | p value* |
|--------------------|----------|-------------|-------------|--------------|----------|
| Sex                | Female   | 122         | 44 (78)     | 78           | 0.008    |
|                    | Male     | 322         | 74 (248)    |              |          |
| Stage              | I        | 27          | 11 (16)     | 16           | 0.358    |
|                    | II       | 70          | 19 (51)     | 51           |          |
|                    | III      | 81          | 22 (59)     | 59           |          |
|                    | IV       | 266         | 66 (200)    | 200          |          |
| T status           | T1       | 42          | 15 (27)     | 27           | 0.491    |
|                    | T2       | 119         | 35 (94)     | 94           |          |
|                    | T3       | 98          | 26 (72)     | 72           |          |
|                    | T4       | 175         | 42 (133)    | 133          |          |
| Lymph node status  | Negative | 204         | 65 (139)    | 139          | 0.024    |
|                    | Positive | 240         | 53 (187)    | 187          |          |

* p value < 0.05 was considered statistically significant (chi-square test for categorical variables).
with HNSCC were significantly associated with sex ($p = 0.008$) and positive lymph node metastasis ($p = 0.024$) (Table 1).

### 3.2 UBE2C knockdown reduced invasion and migration abilities of the HNSCC cells

Clinical findings suggest that UBE2C plays a role in HNSCC progression. We evaluated the effects of UBE2C knockdown on the migration, invasion, colony formation and proliferation abilities of oral cancer cells. As shown in Figure 3A, the expression levels of UBE2C decreased after silencing via lentiviral-mediated RNAi. Knockdown of UBE2C expression in SAS and CAL27 HNSCC cell lines significantly reduced their migration, invasion and colony formation abilities compared with shluc control cells (Figure 3B, 3C and Figure S3). Moreover, knockdown of UBE2C did not affect the viability of SAS and CAL27 cells (Figure 3D).
3.3 | UBE2C downregulated the inhibitory glycolysis pathway in the HNSCC cells

To determine the molecular mechanism of the metabolic pathway by which UBE2C regulates cancer cell progression, we downloaded GSE32873 and analysed differential gene expression between control PC3 cells and UBE2C-knockdown PC3 cells. By filtering the gene signature enzyme annotation in addition to ingenuity pathway analysis (IPA), the glycolysis I pathway was significantly downregulated in UBE2C-knockdown cancer cells (Figure 4A and Table S1). Six gene-encoding enzymes involved in the glycolysis biosynthetic pathway were downregulated in UBE2C knockdown cells: (1) aldolase, fructose-bisphosphate A (ALDOA), (2) triosephosphate isomerase 1 (TPI1), (3) phosphoglycerate kinase 1 (PGK1), (4) phosphoglycerate mutase 1 (PGAM1), (5) phosphoglycerate mutase family member 4 (PGAM4) and (6) pyruvate kinase M1/2 (PKM) (Figure 4B). We next examined whether UBE2C modulated the glycolysis pathway in SAS and CAL27 cells. We confirmed these results using quantitative reverse transcription polymerase chain reaction (RT-qPCR), which showed that ALDOA, TPI1, PKG1, PGAM1, PGAM4 and PKM were significantly downregulated in UBE2C-knockdown SAS and CAL27 cells compared with the control cells (Figure 4C). Moreover, UBE2C knockdown significantly reduced lactate levels in HNSCC cells (Figure S4).

3.4 | UBE2C expression correlated with the enzymes of a glycolysis pathway in patients with HNSCC

We next examined the overall survival rates of ALDOA, TPI1, PGK1, PGAM1, PGAM4 and PKM via an online survival analysis of patients with HNSCC (http://www.oncolnc.org/). High levels of ALDOA (p = 0.025), TPI1 (p = 0.0462), PGK1 (p = 0.00155), PGAM1 (p = 0.0391) and PGAM4 (p = 0.00698) were associated with poor overall survival (Figure 5A). We further examined the correlation between UBE2C and genes of the glycolysis I pathway in patients with HNSCC using the TCGA dataset. We found that UBE2C levels were significantly positively correlated with ALDOA, TPI1, PGK1, PGAM1 and PKM levels in patients with HNSCC (Figure 5B).

3.5 | UBE2C promotes cell migration/invasion through the hypoxia inducible factor 1 subunit alpha (HIF-1α) signalling pathway

Based on GSE32873 (Figure 4A), a gene annotation enrichment analysis was performed to identify transcription factors which showed that HIF-1α signalling was inhibited upon UBE2C-knockdown (Figure 6A and Table S2). It has been demonstrated that HIF-1α regulation
glycolysis occurs in cancer cells.\textsuperscript{19} We confirmed whether UBE2C modulated the expression of HIF-1$\alpha$ in HNSCC cells. Knockdown of UBE2C in CAL27 and SAS significantly reduced HIF-1$\alpha$ expression (Figure 6B). Next, we evaluated whether UBE2C mediated migration/invasion and colony formation capabilities in UBE2C knockdown cells. Treatment with CoCl$_2$ (a HIF-1$\alpha$ inducer) restored the expression of HIF-1$\alpha$, TPI1, PGK1, PGAM1, PGAM4 and PKM, as well as the migration/invasion capabilities in the UBE2C knockdown cells (Figure 6C,D and Figure S5). These data suggest that UBE2C enhances cell migration and invasion abilities through HIF-1$\alpha$ signalling.

**4 | DISCUSSION**

In this study, the UBE2 family was assessed in patients with HNSCC, and high levels of UBE2C were identified as a signifier for poor prognosis in patients. High levels of UBE2C expression were also correlated with lymph node metastasis, indicating that the enzyme plays an important role in HNSCC metastasis. Although other members of the UBE2 family have been implicated for their role in cancer metastasis, the UBE2O-AMPK$\alpha$2 axis, for example, was found to promote breast cancer metastasis. \textsuperscript{20} We have shown that these members are unrelated to the poor survival of patients with HNSCC.

An earlier study reported that the von Hippel–Lindau protein (pVHL) is responsible for modulating HIF-1$\alpha$ expression \textsuperscript{21–24} A separate study described how UBE2C regulates HIF-1$\alpha$ expression by ubiquitinating and degrading pVHL (an upstream regulator of HIF-1$\alpha$) in human aortic valve endothelial cells. \textsuperscript{25} In the present study, knockdown of UBE2C significantly reduced the invasion/migration and colony formation abilities of HNSCC cells (Figure 3B,C). Our data illustrated that UBE2C mediates the invasion and migration capabilities through the HIF-1$\alpha$ pathway in
HNSCC cells. In agreement with our results, Nora et al. showed that CoCl₂ treatment significantly increased cell motility in YS1.2 and YS1.8 cells. Meanwhile, our data showed that treatment with CoCl₂ restored the invasion/migration abilities in UBE2C knockdown cells (Figure 6D). These findings suggest that UBE2C-HIF-1α signalling promotes HNSCC cell invasion.

Furthermore, we showed that UBE2C mediated both the glycolysis pathway and the expression of HIF-1α in HNSCC cells (Figures 4C and 6B). Previous studies have shown that HIF-1α is involved in regulating the glycolysis pathway. In hypoxic stimuli, HIF-1α-induced glucose transporter 1 (GLUT1) expression increases glucose uptake and supports glycolysis in cancer cells. HIF-1α was also found to both modulate ALDOA expression and increase lactate levels, leading to upregulation of MMP9, thereby promoting an invasion of lung cancer cells in vitro and in vivo. Similarly, our data showed that UBE2C regulated the expression of HIF-1α and glycolysis enzymes in HNSCC cells. Knockdown of UBE2C reduced lactate levels in HNSCC cells. CoCl₂-induced HIF-1α expression restored migration and invasion abilities as well as the glycolysis pathway in HNSCC cells. Based on these findings, we surmised that HIF-1α is regulated by UBE2C, resulting in both a regulated glycolysis pathway as well as the advancement of the HNSCC cells’ invasion ability.
Other mechanistic pathways have been suggested for UBE2C. In a previous study, treatment with CCI779 (mTORC1 complex inhibitor) inhibited UBE2C expression and tumour growth in cervical cancer in vitro and in vivo. UBE2O, a UBE2 member, targets AMPKα2 for ubiquitination and degradation, leading to an increase in the mTORC1-HIF-1α pathway. UBE2O modulates cancer progression through the AMPKα2-mTORC1-HIF-1α axis in cancer cells. Moreover, inhibition of UBE2O reduced glucose consumption and lactate levels in HAP1 cells. Our data showed that UBE2C regulated both the glycolysis pathway and invasion ability through HIF-1α signalling in HNSCC cells.

Metabolic reprogramming is a hallmark of cancer and is implicated in cancer progression contributing to signal transduction and metastasis. High glucose levels generate lactate secretion into the extracellular space, which may create a tumour microenvironment favourable for cancer cell migration and angiogenesis. Moreover, HIF-1α-modulated ALDOA upregulated expression in lung cancer cells. Meanwhile, ALDOA overexpression promoted lactate production in order to block prolyl hydroxylase (PHD) activities, leading to HIF-1α stabilization, thereby promoting metastasis. Our data showed that knockdown of UBE2C reduced the expression of ALDOA in HNSCC cells. UBE2C-upregulated expression correlates with ALDOA expression in patients with HNSCC. High ALDOA expression was also associated with poor overall survival. In this study, we demonstrated that UBE2C mediates the glycolysis pathway and invasion ability, thereby providing a therapeutic target for HNSCC metastasis.

5 CONCLUSION

After evaluating the expression of the UBE2 family in this study, upregulated UBE2C was identified to be associated with lymph node metastasis in patients with HNSCC. Moreover, this study is the first to investigate the mechanism by which UBE2C modulates the migration/invasion abilities and glycolysis pathway of HNSCC cells through HIF1-α signalling. Here, we found that UBE2C expression was correlated with lymph node metastasis in patients with HNSCC, indicating that UBE2C is an independent prognostic factor.

AUTHOR CONTRIBUTIONS

Yi-Fang Yang: Formal analysis (equal); funding acquisition (equal); writing – original draft (equal). Yu-Chan Chang: Funding acquisition (equal); validation (equal). Kuo-Wang Tsai: Resources (equal). Ming-Hsin Hung: Data curation (equal). Bor-Hwang Kang: Funding acquisition (equal); writing – review and editing (equal).

ACKNOWLEDGEMENT

This study was supported by grants from Kaohsiung Veterans General Hospital, Taiwan [grant number VGHKS109-115(B.-H.K.), KSVGH110-097(B.-H.K) and KSVGH110-144(Y.-F.Y.)], Yen Ting Ling Medical Foundation [CI-111-7 (Y.-F.Y) and CI-111-9 (Y.-C.C)], Veterans General Hospitals and University System of Taiwan Joint Research Program [VGHUST111-G3-3-1(Y.-F.Y) and VGHUST111-G3-3-2 (Y.-C.C)], National Health Research Institutes [grant number NHRI-109BCCO-MF-202012-03(B.-H.K)], S VGH, TSHG, AS Joint Research Program [VTA111-A-3-1 and VTA111-A-3-2(Y.F.Y)] and National Science Council [MOST 110-2314-B-075B-009-MY3 (Y.F.Y)].

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

DATA AVAILABILITY STATEMENT

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

ORCID

Yi-Fang Yang https://orcid.org/0000-0001-7425-3156
Yu-Chan Chang https://orcid.org/0000-0003-0474-9935
Kuo-Wang Tsai https://orcid.org/0000-0002-9028-9834
Bor-Hwang Kang https://orcid.org/0000-0003-3788-448X

REFERENCES

1. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. Oral Oncol. 2007;43(6):523-534. doi:10.1016/j.oraloncology.2006.11.010
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi:10.3322/caac.20070
3. Holliday R. Response to Jonathan bard and Aubrey de Grey. Bioessays. 2000;22(2):207. doi:10.1002/(SICI)1521-1878(200002)22:2%3E2.0.CO;2-M
4. Kowalski LP, Bagietto R, Lara JR, Silva JF Jr, Magrin J. Prognostic significance of the distribution of neck node metastasis from oral carcinoma. Head Neck. 2000;22(3):207-214. doi:10.1002/(SICI)1097-0347(200003)22:3%3E2.0.CO;2-9
5. Kim SJ, Shin HJ, Jung KY, et al. Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol. 2007;37(11):812-819. doi:10.1093/jjco/hym121
6. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143-1154. doi:10.1056/NEJMra0707975
7. Pfister DG, Spencer S, Brizel DM, et al. Head and neck cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13(7):847-855; quiz 856. doi:10.6004/jnccn.2015.0102
8. Nguyen DX, Bos MD, Massage J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274-284. doi:10.1038/nrc2622
9. Buchakjian MR, Kornbluth S. The engine driving the ship: metabolic steering of cell proliferation and death. Nat Rev Mol Cell Biol. 2010;11(10):715-727. doi:10.1038/nrm2972
10. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472-482. doi:10.1016/j.ccr.2008.05.005
11. Gordan JD, Lal P, Donedeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008;14(6):435-446. doi:10.1016/j.ccr.2008.10.016
12. Zhang WC, Shyh-Chang N, Yang H, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells...
and tumorigenesis. Cell. 2012;148(1-2):259-272. doi:10.1016/j.cell.2011.11.050

13. Nelson ER, Wardell SE, Jasper JS, et al. 27-hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094-1098. doi:10.1126/science.1241908

14. Wu Q, Ishikawa T, Sirianni R, et al. 27-hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 2013;5(3):637-645. doi:10.1016/j.celrep.2013.10.006

15. Williamson A, Wickliffe KE, Mellone BG, Song L, Karpen GH, Rape M. Identification of a physiological E2 module for the human anaphase-promoting complex. Proc Natl Acad Sci USA. 2009;106(43):18213-18218. doi:10.1073/pnas.0907887106

16. Liu PF, Chen CF, Shu CW, et al. UBE2C is a potential biomarker for tumorigenesis and prognosis in tongue squamous cell carcinoma. Diagnostics (Basel). 2020;10(9):674. doi:10.3390/diagnostics10090674

17. Jin Z, Zhao X, Cui L, et al. UBE2C promotes the progression of head and neck squamous cell carcinoma. Biochem Biophys Res Commun. 2020;523(5):389-397. doi:10.1016/j.bbrc.2019.12.064

18. Kuner R, Falth M, Pressinotti NC, et al. The Maternal Embryonic Leucine Zipper Kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl). 2013;91(2):237-248. doi:10.1007/s00109-012-0949-1

19. Lum JJ, Bui T, Gruber M, et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007;21(9):1037-1049. doi:10.1101/gad.1529107

20. Vila IK, Yao Y, Kim G, et al. A UBE2O-AMPKalpha2 Axis that promotes tumor initiation and progression offers opportunities for therapy. Cancer Cell. 2017;31(2):208-224. doi:10.1016/j.ccell.2017.01.003

21. Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL-HIF-1 system. A key mediator of oxygen homeostasis. Adv Exp Med Biol. 2001;502:365-376.

22. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732. doi:10.1038/nrc1187

23. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010;40(2):294-309. doi:10.1016/j.molcel.2010.09.022

24. Gao L, Chen Q, Zhou X, Fan L. The role of hypoxia-inducible factor 1 in atherosclerosis. J Clin Pathol. 2012;65(10):872-876. doi:10.1136/jclinpath-2012-200828

25. Fernandez Esmerats J, Villa-Roel N, Kumar S, et al. Disturbed flow increases UBE2C (ubiquitin E2 ligase C) via loss of miR-483-3p, inducing aortic valve calcification by the pVHL (von Hippel-Lindau protein) and HIF-1alpha (hypoxia-inducible factor-1alpha) pathway in endothelial cells. Arterioscler Thromb Vasc Biol. 2019;39(3):467-481. doi:10.1161/ATVBAHA.118.312233

26. Barrack NH, Khajah MA, Luqmani YA. Hypoxic environment may enhance migration/penetration of endocrine resistant MCF7-derived breast cancer cells through monolayers of other non-invasive cancer cells in vitro. Sci Rep. 2020;10(1):1127. doi:10.1038/s41598-020-58055-x

27. Nagao A, Kobayashi M, Koyasu S, Chow CCT, Harada H. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci. 2019;20(2):238. doi:10.3390/ijms20020238

28. Chang YC, Chan YC, Chang WM, et al. Feedback regulation of ALDOA activates the HIF-1alpha/MMP9 axis to promote lung cancer progression. Cancer Lett. 2017;403:28-36. doi:10.1016/j.canlet.2017.06.001

29. Chiang AJ, Li CJ, Tsui KH, et al. UBE2C drives human cervical cancer progression and is positively modulated by mTOR. Biomolecules. 2020;11(1):37. doi:10.3390/biom11010037

30. Nakazato K, Mogushi K, Kayamori K, et al. Glucose metabolism changes during the development and progression of oral tongue squamous cell carcinomas. Oncol Lett. 2019;18(2):1372-1380. doi:10.3892/ol.2019.10420

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Yang Y-F, Chang Y-C, Tsai K-W, Hung M-H, Kang B-H. UBE2C triggers HIF-1α-glycolytic flux in head and neck squamous cell carcinoma. J Cell Mol Med. 2022;26:3716-3725. doi: 10.1111/jcmm.17400